BQ123 selectively improved tumor perfusion and enhanced nanomedicine delivery for glioblastomas treatment.

Abstract

Blood perfusion was always lower in tumor tissues as compared with that in surrounding normal tissues which lead to inadequate nanomedicine delivery to tumors. Inspired by the upregulation of both endothelin-1 (ET1) and its ETA receptor in tumor tissues and the crucial contribution of ET1-ETA receptor signaling to maintain myogenic tone of tumor vessels, we supposed that inhibition of ET1-ETA receptor signaling might selectively improve tumor perfusion and help deliver nanomedicine to tumors. Using human U87 MG glioblastomas with abundant vessels as the tumor model, immunofluorescence staining demonstrated that ETA receptor was overexpressed by in glioblastomas tissues compared with normal brain tissues. A single administration of ETA receptor antagonist BQ123 at the dose of 0.5 mg/kg could effectively improve tumor perfusion which was evidenced by in vivo photoacoustic imaging. Additionally, a single treatment of BQ123 could significantly improve the accumulation of nanoparticles (NPs) around 115 nm in tumors with a more homogeneous distribution pattern by in vivo imaging, ex vivo imaging as well as in vivo distribution experiments. Furthermore, BQ123 successfully increased the therapeutic benefits of paclitaxel-loaded NPs and significantly elongated the survival time of orthotropic glioblastomas-bearing animal models. In summary, the present study provided a new strategy to selectively improve tumor perfusion and therefore benefit nanomedicine delivery for tumor therapy. As ET1-ETA receptor signaling was upregulated in a variety of tumors, this strategy might open a new avenue for tumor treatment.

• Authors: Bo Zhang, Honglan Wang, Kai Jin, Ting Jiang, Shun Shen, Zimiao Luo, Yanyan Tuo, Xinguo Jiang, Xianping Liu, Yu Hu, Zhiqing Pang
• Journal: Pharmacological research (Pharmacol Res) Vol. 132 Pg. 211-219 (06 2018) ISSN: 1096-1186 [Electronic] Netherlands
• PMID: 29274786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents, Phytogenic
• Endothelin Receptor Antagonists
• Peptides, Cyclic
• Paclitaxel
• cyclo(Trp-Asp-Pro-Val-Leu)

Topics

• Animals
• Antineoplastic Agents, Phytogenic (administration & dosage, pharmacokinetics)
• Cell Line, Tumor
• Drug Delivery Systems
• Endothelin Receptor Antagonists (administration & dosage, pharmacokinetics)
• Glioblastoma (drug therapy, metabolism)
• Humans
• Male
• Mice, Inbred BALB C
• Mice, Nude
• Nanoparticles (administration & dosage)
• Paclitaxel (administration & dosage, pharmacokinetics)
• Peptides, Cyclic (administration & dosage)